Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hepatitis C therapies - Merck

Drug Profile

Research programme: hepatitis C therapies - Merck

Alternative Names: HCV NS5A inhibitors - Idenix; IDX 19368; IDX 316; IDX-136; IDX-20963; IDX077; IDX102; IDX791; IDXSCA; IDXSCB; NV 08; NV 08B; Uridine nucleoside - Idenix; Uridine nucleotide analog - Idenix; Uridine nucleotide prodrug - Idenix

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idenix Pharmaceuticals; University of Cagliari
  • Developer Merck & Co
  • Class Macrocyclic compounds; Nucleosides
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
  • 07 Apr 2014 Idenix discontinues the development of IDX 20963
  • 20 Jun 2013 The US FDA places a hold on the initiation of clinical trials for IDX 20963 in Hepatitis C
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top